《美股业绩》Gilead季绩胜预期 惟瑞德西韦销售逊预期
生产瑞德西韦的美国药厂吉利德科学(Gilead Sciences)公布第三季度业绩。季度纯利3.6亿美元,对上年度同期亏损11.65亿美元。每股季度摊薄纯利29美仙,经调整後为2.11美元,较市场预期高21美仙,季度派息每股68美仙。季度收入65.77亿美元,按年升17%,高於市场预期的63.1亿美元。
瑞德西韦季度销售8.73亿美元,差於市场预期的9.6亿美元。公司表示,今年夏季疫情期间更多年轻人染病,但入院率减少影响瑞德西韦需求。公司仍预期秋冬季疫情反弹下,瑞德西韦需求上升。公司全年度预测销售上限为235亿美元,低於市场预期的241亿美元,亦低於公司原来预期的250亿美元。
吉利德科学股价在延长交易时段跌1.7%,报57.75美元,创52周低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.